Invention Grant
- Patent Title: Methods for therapeutic administration of messenger ribonucleic acid drugs
-
Application No.: US15761220Application Date: 2016-10-05
-
Publication No.: US10849920B2Publication Date: 2020-12-01
- Inventor: Stephen Hoge , Tirtha Chakraborty , Gilles Besin , Ruchi Jain
- Applicant: ModernaTX, Inc.
- Applicant Address: US MA Cambridge
- Assignee: ModernaTX, Inc.
- Current Assignee: ModernaTX, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Amy E. Mandragouras, Esq.; Ariana D. Harris
- International Application: PCT/US2016/055582 WO 20161005
- International Announcement: WO2017/062513 WO 20170413
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/04 ; A61K31/7115 ; C12N15/67 ; A61K9/00 ; A61K9/127 ; C12N15/113

Abstract:
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
Public/Granted literature
- US20180256628A1 METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS Public/Granted day:2018-09-13
Information query